Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents

• Status: Unknown status
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Current treatment guidelines indicate that oral antiviral agents for HBeAg-positive chronic hepatitis B virus infection (CHB) can be stopped if the patient has undergone HBeAg seroconversion with HBV-DNA loss measured at two consecutive occasions at least 6 months apart (primary treatment endpoint). Stopping treatment can be considered if undetectable HBV-DNA has been documented on three separate occasions 6 months apart in HBeAg-negative patients. However, oral antiviral drugs currently approved for the treatment of CHB have relatively limited sustained long-term efficacy and a large proportion of patients will suffer from HBV recurrence after stopping treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
• Treatments: Antiviral Agents; Lamivudine

Criteria

Inclusion Criteria:

1. Male and female patients >=18 years of age

2. Negative serum HBV DNA within 3 months prior to entry

3. ALT <1.5 ULN within 3 months prior to entry

4. Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of test drug. Additionally, all fertile males with partners of childbearing age and females of the Lamivudine treatment arm must be using reliable contraception during the study and for 6 months after treatment completion.

Exclusion Criteria:

1. Women with ongoing pregnancy or breast feeding

2. Therapy with any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) *6 months prior to the first dose of study drug

3. Any investigational drug *6 weeks prior to the first dose of study drug

4. Co-infection with active hepatitis A, hepatitis C and/or human immunodeficiency virus (HIV)

5. Patients who have virological evidence of Lamivudine-associated YMDD mutants.

6. Patients who have clinical evidence of liver cirrhosis or hepatocellular carcinoma.

7. History or other evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures)

8. Signs or symptoms of hepatocellular carcinoma

9. History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease

10. Neutrophil count <1500 cells/mm3 or platelet count <90,000 cells/mm3 at screening

11. Serum creatinine level >1.5 times the upper limit of normal at screening

12. History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease

13. History of a severe seizure disorder or current anticonvulsant use

14. History of immunologically mediated disease, chronic pulmonary disease associated with functional limitation, severe cardiac disease, major organ transplantation or other evidence of severe illness, malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study

15. Evidence of drug abuse (including excessive alcohol consumption) within one year of study entry

16. Inability or unwillingness to provide informed consent or abide by the requirements of the study